Mangoceuticals, Inc. (MGRX)
- Previous Close
1.7700 - Open
1.7210 - Bid 1.6600 x 100
- Ask 1.8800 x 100
- Day's Range
1.7106 - 1.8000 - 52 Week Range
1.4850 - 16.8000 - Volume
23,494 - Avg. Volume
271,444 - Market Cap (intraday)
8.864M - Beta (5Y Monthly) 2.46
- PE Ratio (TTM)
-- - EPS (TTM)
-4.8400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. The company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
www.mangoceuticals.com3
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MGRX
View MorePerformance Overview: MGRX
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MGRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MGRX
View MoreValuation Measures
Market Cap
9.15M
Enterprise Value
9.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.69
Price/Book (mrq)
0.66
Enterprise Value/Revenue
15.11
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-62.72%
Return on Equity (ttm)
-118.31%
Revenue (ttm)
615.87k
Net Income Avi to Common (ttm)
-9.58M
Diluted EPS (ttm)
-4.8400
Balance Sheet and Cash Flow
Total Cash (mrq)
58.65k
Total Debt/Equity (mrq)
1.54%
Levered Free Cash Flow (ttm)
-929.17k